News
NewAmsterdam Pharma To Present New Analysis From The Phase 2 ROSE2 Trial Evaluating Obicetrapib In Combination With Ezetimibe At 2024 American College Of Cardiology Congress
25 Mar 24
Biotech, News, General
Scotiabank Initiates Coverage On NewAmsterdam Pharma with Sector Outperform Rating, Announces Price Target of $35
14 Mar 24
News, Price Target, Initiation, Analyst Ratings
Press releases
BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
9 Apr 24
Press Releases
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
9 Apr 24
Press Releases